Cymabay Therapeutics Inc (CBAY)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cymabay Therapeutics Inc chart...

About the Company

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.

CEO

Sujal Shah

Exchange

NASDAQ

Website

http://www.cymabay.com/

$10M

Total Revenue

66

Employees

$4B

Market Capitalization

-34.87

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CBAY News

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production

on MSN ago, source:

Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer ...

3 Dividend Stocks to Buy Hand Over Fist in March

on MSN ago, source:

Get paid to own a stock whether it moves higher or lower. What a concept! And it's one that any investor who buys dividend ...

Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure

18d ago, source:

Analyst Ed Arce of H.C. Wainwright maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of ...

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

on MSN ago, source:

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Perrigo has no exposure to infant formula litigation, CG says

on MSN ago, source:

Perrigo (PRGO) has no exposure to lawsuits over the safety of premature infant formula that have been filed against rivals ...

Buy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Position

3d ago, source:

Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Cymabay Therapeutics Inc (NASDAQ: CBAY) Up 271.63% This Year: What Is Going To Happen Next

12d ago, source:

Cymabay Therapeutics Inc (NASDAQ:CBAY) price is hovering higher on Wednesday, March 06, jumping 0.17% above its previous close. A look at today’s price movement shows that the recent level at last ...

GILD Jan 2025 110.000 put

6d ago, source: Yahoo Finance

March 11, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s ...

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

7d ago, source: 雅虎財經

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust ...

iRhythm Technologies, Inc.

12d ago, source: CNN

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services ...

Before Buying Cyclo Therapeutics Inc (NASDAQ: CYTH) Stock, Read This First

5d ago, source:

Cyclo Therapeutics Inc (NASDAQ:CYTH) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $1.62. Actively observing the price movement ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...